Physician profile
Abigail Chan
NPI 1942720719
$7,573.87
in general payments reported to CMS, 2019-2025
44 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $403 · 2021: $1,606 · 2022: $2,434 · 2023: $1,558 · 2024: $477 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,924.88 |
| Education | $206.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,090.17 | 2020-2023 | Lumakras, Kyprolis |
| Seagen INC. | $610.71 | 2022-2023 | Adcetris, Tukysa, Padcev |
| Genzyme Corporation | $564.11 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $510.18 | 2020-2023 | Tavalisse, Rezlidhia |
| Incyte Corporation | $495.49 | 2021-2023 | Monjuvi |
| Daiichi Sankyo INC. | $381.25 | 2021-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $374.27 | 2020-2025 | Keytruda, Keytruda Qlex, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $265.24 | 2021-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $244.31 | 2020-2023 | Lynparza, Tagrisso |
| Novartis Pharmaceuticals Corporation | $213.75 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $203.59 | 2020-2023 | Libtayo |
| Gilead Sciences, INC. | $200.58 | 2021-2025 | Trodelvy |
| Emd Serono, INC. | $182.63 | 2020-2022 | |
| Astellas Pharma US INC | $153.80 | 2024-2025 | Vyloy, Xospata |
| Celgene Corporation | $153.29 | 2022-2025 | Opdivo, Reblozyl |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $152.83 | 2021-2023 | Imbruvica |
| Adc Therapeutics America, INC. | $150.90 | 2023 | |
| Terumo Medical Corporation | $146.35 | 2025 | Glidewire, Angio-Seal, Metacross Otw |
| Beigene USA, INC. | $144.98 | 2021-2023 | Brukinsa |
| Mirati Therapeutics, INC. | $124.74 | 2023-2024 | Krazati |
| Coherus Oncology, INC. | $122.99 | 2022-2023 | |
| Adaptive Biotechnologies Corporation | $122.79 | 2022 | |
| Pfizer INC. | $108.23 | 2021-2025 | |
| Abbvie INC. | $101.22 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.91 | 2020-2024 | Gilotrif |
| Bayer Healthcare Pharmaceuticals INC. | $80.95 | 2022-2024 | |
| Eisai INC. | $76.51 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.49 | 2024-2025 | Fruzaqla |
| Deciphera Pharmaceuticals INC. | $63.98 | 2021-2025 | Romvimza, Qinlock |
| Sobi, INC | $58.24 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $40.73 | 2022-2023 | Tazverik |
| Array Biopharma INC | $32.63 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Stemline Therapeutics INC. | $31.95 | 2024 | Elzonris |
| Kite Pharma, INC. | $23.96 | 2022 | |
| Jazz Pharmaceuticals INC. | $23.15 | 2025 | |
| Glaxosmithkline, LLC. | $21.11 | 2025 | Ojjaara |
| Agios Pharmaceuticals, INC. | $19.81 | 2025 | Pyrukynd |
| Cti Biopharma Corp. | $19.25 | 2022 | |
| Kyowa Kirin, INC. | $18.66 | 2023 | Poteligeo |
| Alexion Pharmaceuticals, INC. | $18.32 | 2025 | Ultomiris |
| Tersera Therapeutics LLC | $17.86 | 2025 | Zoladex |
| G1 Therapeutics, INC. | $17.28 | 2023 | Cosela |
| Apellis Pharmaceuticals, INC. | $15.70 | 2022 | |
| Lilly USA, LLC | $13.98 | 2025 | Verzenio, Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.